• Retatrutide is a triple-hormone agonist (GLP-1/GIP/glucagon) showing record-breaking fat-loss results in clinical trials.

• Cagrilintide is an amylin analog that enhances satiety and may complement GLP drugs.

• Combined, they could form a next-gen weight loss injections stack,  targeting appetite, metabolism, and energy expenditure.

• Early data suggest this duo may surpass Ozempic® (semaglutide) in both speed and magnitude of results.

• Both drugs are still under investigation; safety, dosing, and FDA approval are pending.

Retatrutide (LY3437943) is Eli Lilly’s experimental triple-agonist drug that activates:

1. GLP-1 (Glucagon-like peptide-1) – reduces appetite and slows digestion

2. GIP (Glucose-dependent insulinotropic peptide) – enhances insulin sensitivity

3. Glucagon receptor – increases fat metabolism and energy expenditure

In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction—rivaling or even surpassing bariatric surgery outcomes.

Cagrilintide (NN00739) is a synthetic analog of amylin, a hormone released with insulin that promotes satiety and slows gastric emptying.

It works differently from GLP-1 drugs, acting as a complementary mechanism:

• Increases fullness signals to the brain

• Decreases cravings and meal frequency

• Helps sustain steady blood-sugar control

Cagrilintide has been studied both as a solo treatment and in combination with semaglutide, showing synergistic weight-loss effects beyond either alone.

Researchers are now exploring the potential synergy between Retatrutide + Cagrilintide, combining GLP-1/GIP/glucagon activation with amylin signaling for multi-pathway fat loss.

This stack could theoretically:

• Suppress appetite more effectively than semaglutide

• Enhance calorie burn via glucagon activation

• Preserve lean mass while reducing fat mass

• Stabilize hunger hormones for long-term maintenance

In early data and preclinical models, this combination produced unprecedented fat-loss percentages, suggesting a paradigm shift in obesity medicine.

Potential Benefits:

• Greater total fat loss

• Reduced hunger and cravings

• Possible metabolic improvements beyond semaglutide

• May help maintain results long-term

Considerations:

• Not yet FDA-approved

• Side effects may overlap (nausea, constipation, fatigue)

• Long-term safety data still limited

The combination of Retatrutide + Cagrilintide represents the next evolution of metabolic pharmacology, one that treats obesity like the complex, multi-hormonal disease it is.

At Leva Medical, our specialists closely track these clinical developments to ensure patients in Queens, Elmhurst, and Forest Hills have access to the safest and most effective options available.